Key Takeaways Phibro's rally stems from strong Animal Health traction, led by MFAs, nutritional products and vaccines.PAHC boosted its MFA lineup with Zoetis' assets and saw Q1 MFA revenues grow 81% on broad product strength.Phibro's global expansion drove sharp sales jumps in the EMEA and Asia Pacific amid rising vaccine demand.Phibro Animal Health (PAHC) shares have surged 59.6% so far this year, demonstrating impressive momentum. The performance outpaced the industry’s 2.8% fall and the S&P 500 Composite ...